Daptomycin eluted from calcium sulfate appears effective against Staphylococcus.
The emergence of resistant strains of Gram-positive organisms in osteomyelitis creates treatment challenges. Daptomycin is an antibiotic that shows promise for treating some resistant strains of Gram-positive infections; however, it has not been widely used clinically for the treatment of osteomyelitis. We determined whether daptomycin eluted from calcium sulfate-a local delivery vehicle used for the treatment of osteomyelitis-retained activity against Gram-positive bacteria. Daptomycin was mixed with calcium sulfate hemihydrate, with both laboratory powder and a commercial kit, to form a hardened pellet. Daptomycin was eluted from calcium sulfate and retained its ability to inhibit bacterial growth of Staphylococcus aureus and Staphylococcus epidermidis for eluates gathered up to 28 days. Our preliminary data demonstrates sterilized pellets with daptomycin retained their ability to inhibit bacterial growth of certain strains of Gram-positive organisms.
Webb
Nathan D
ND
University of Memphis, Memphis, TN, USA. nwebb1@memphis.edu
McCanless
Jonathan D
JD
Courtney
Harry S
HS
Bumgardner
Joel D
JD
Haggard
Warren O
WO
D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics*; D018786:Bone Substitutes / Q000493:pharmacokinetics*; D002133:Calcium Sulfate / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D017576:Daptomycin / Q000493:pharmacokinetics*; D004343:Drug Implants; D010539:Permeability; D013053:Spectrophotometry; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development; D013212:Staphylococcus epidermidis / Q000187:drug effects* / Q000254:growth & development
D000900:Anti-Bacterial Agents; D018786:Bone Substitutes; D004343:Drug Implants; D017576:Daptomycin; D002133:Calcium Sulfate